Quantitative Evaluation of the Economic Impact of Antimicrobial Resistance on the Treatment of Community-Acquired Acute Pyelonephritis in Korea.

Infection & chemotherapy Pub Date : 2022-09-01 Epub Date: 2022-07-27 DOI:10.3947/ic.2022.0057
Taul Cheong, Jungmo Ahn, Yun Seop Kim, Hyunjoo Pai, Bongyoung Kim
{"title":"Quantitative Evaluation of the Economic Impact of Antimicrobial Resistance on the Treatment of Community-Acquired Acute Pyelonephritis in Korea.","authors":"Taul Cheong,&nbsp;Jungmo Ahn,&nbsp;Yun Seop Kim,&nbsp;Hyunjoo Pai,&nbsp;Bongyoung Kim","doi":"10.3947/ic.2022.0057","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The proportion of antimicrobial-resistant <i>Enterobacteriales</i> as a causative pathogen of community-acquired acute pyelonephritis (APN) has been increasing. The aim of this study was to quantitatively evaluate the impact of antimicrobial resistance on medical costs and length of hospital stay for the treatment of APN.</p><p><strong>Materials and methods: </strong>A single-center retrospective cohort study was conducted between January 2018 and December 2019. All hospitalized patients aged ≥19 years who were diagnosed with community-acquired APN were recruited, and those diagnosed with <i>Enterobacteriales</i> as a causative pathogen were included. Log-linear regression analysis was performed to determine the risk factors for medical costs and length of hospital stay.</p><p><strong>Results: </strong>A total of 241 patients participated in this study. Of these, 75 (31.1%) and 87 (36.1%) had extended-spectrum beta-lactamase (ESBL)-producing pathogens and ciprofloxacin-resistant pathogens as the causative pathogen, respectively. Based on the log-linear regression model, ESBL-producing <i>Enterobacteriales</i> is a causative pathogen that is, on average, 27.0%, or United States Dollar (USD) 1,211 (<i>P</i> = 0.026) more expensive than non-ESBL-producing <i>Enterobacteriales</i>. A patient who is a year older would incur USD 23 (<i>P</i> = 0.040) more, those having any structural problems in the urinary tract would incur USD 1,231 (<i>P</i> = 0.015) more, and those with a unit increase in the Pitt bacteremia score would incur USD 767 (<i>P</i> <0.001) more, with all other variables constant. Having a case in which ESBL-producing <i>Enterobacteriales</i> is a causative pathogen would explain staying 22.0% longer or 2 more days (<i>P</i> = 0.050) in the hospital than non-ESBL-producing <i>Enterobacteriales</i>. A patient who is 10 years older would, on average, would have to stay for half a day longer (<i>P</i> = 0.045). Any structural problems in the urinary tract explain a longer stay (2.4 days longer; <i>P</i> = 0.032), and moving from 0 to 5 on the Pitt bacteremia score would explain four more days (<i>P</i> = 0.038) in the hospital.</p><p><strong>Conclusion: </strong>Patients with community-acquired APN with ESBL-producing Enterobacteriale as the causative pathogen would incur, on average, 27.0% higher medical costs and 22.0% longer hospitalization days than patients detected with non-ESBL-producing pathogens.</p>","PeriodicalId":520645,"journal":{"name":"Infection & chemotherapy","volume":" ","pages":"456-469"},"PeriodicalIF":0.0000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2a/5d/ic-54-456.PMC9533169.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection & chemotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3947/ic.2022.0057","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/7/27 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Background: The proportion of antimicrobial-resistant Enterobacteriales as a causative pathogen of community-acquired acute pyelonephritis (APN) has been increasing. The aim of this study was to quantitatively evaluate the impact of antimicrobial resistance on medical costs and length of hospital stay for the treatment of APN.

Materials and methods: A single-center retrospective cohort study was conducted between January 2018 and December 2019. All hospitalized patients aged ≥19 years who were diagnosed with community-acquired APN were recruited, and those diagnosed with Enterobacteriales as a causative pathogen were included. Log-linear regression analysis was performed to determine the risk factors for medical costs and length of hospital stay.

Results: A total of 241 patients participated in this study. Of these, 75 (31.1%) and 87 (36.1%) had extended-spectrum beta-lactamase (ESBL)-producing pathogens and ciprofloxacin-resistant pathogens as the causative pathogen, respectively. Based on the log-linear regression model, ESBL-producing Enterobacteriales is a causative pathogen that is, on average, 27.0%, or United States Dollar (USD) 1,211 (P = 0.026) more expensive than non-ESBL-producing Enterobacteriales. A patient who is a year older would incur USD 23 (P = 0.040) more, those having any structural problems in the urinary tract would incur USD 1,231 (P = 0.015) more, and those with a unit increase in the Pitt bacteremia score would incur USD 767 (P <0.001) more, with all other variables constant. Having a case in which ESBL-producing Enterobacteriales is a causative pathogen would explain staying 22.0% longer or 2 more days (P = 0.050) in the hospital than non-ESBL-producing Enterobacteriales. A patient who is 10 years older would, on average, would have to stay for half a day longer (P = 0.045). Any structural problems in the urinary tract explain a longer stay (2.4 days longer; P = 0.032), and moving from 0 to 5 on the Pitt bacteremia score would explain four more days (P = 0.038) in the hospital.

Conclusion: Patients with community-acquired APN with ESBL-producing Enterobacteriale as the causative pathogen would incur, on average, 27.0% higher medical costs and 22.0% longer hospitalization days than patients detected with non-ESBL-producing pathogens.

Abstract Image

Abstract Image

Abstract Image

抗菌药物耐药性对韩国社区获得性急性肾盂肾炎治疗经济影响的定量评价。
背景:耐药肠杆菌作为社区获得性急性肾盂肾炎(APN)病原菌的比例呈上升趋势。本研究的目的是定量评估抗菌药物耐药性对APN治疗的医疗费用和住院时间的影响。材料和方法:2018年1月至2019年12月进行了一项单中心回顾性队列研究。招募所有年龄≥19岁且诊断为社区获得性APN的住院患者,并纳入诊断为肠杆菌作为致病病原体的患者。采用对数线性回归分析确定医疗费用和住院时间的危险因素。结果:共有241例患者参与本研究。其中,产广谱β -内酰胺酶(ESBL)致病菌75例(31.1%),耐环丙沙星致病菌87例(36.1%)。基于对数线性回归模型,产esbl肠杆菌是一种致病病原体,平均比不产esbl肠杆菌贵27.0%,即1211美元(P = 0.026)。年龄大1岁的患者将多花费23美元(P = 0.040),尿路有任何结构性问题的患者将多花费1231美元(P = 0.015),皮特菌血症评分单位增加的患者将多花费767美元(P肠杆菌是一种致病病原体,其住院时间比不产esbl的肠杆菌多22.0%或2天(P = 0.050))。年龄大10岁的患者平均需要多停留半天(P = 0.045)。泌尿道的任何结构性问题都可以解释更长的住院时间(多2.4天;P = 0.032),皮特菌血症评分从0到5可以解释多住院4天的原因(P = 0.038)。结论:以产esbl肠杆菌为病原菌的社区获得性APN患者的医疗费用平均比非产esbl肠杆菌患者高27.0%,住院天数平均比非产esbl肠杆菌患者多22.0%。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信